Literature DB >> 28689856

Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses.

J V Lazarus1, K Safreed-Harmon2, S R Stumo2, M Jauffret-Roustide3, M Maticic4, T Reic5, E Schatz6, J Tallada7, M Harris8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28689856     DOI： 10.1016/j.drugpo.2017.05.054

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN： 0955-3959


× No keyword cloud information.
  7 in total

1.  Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City.

Authors:  Chunki Fong; Pedro Mateu-Gelabert; Courtney Ciervo; Benjamin Eckhardt; Yesenia Aponte-Melendez; Shashi Kapadia; Kristen Marks
Journal:  Drug Alcohol Depend       Date:  2021-02-13       Impact factor: 4.492

2.  Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.

Authors:  Nick Scott; Samuel W Hainsworth; Rachel Sacks-Davis; Alisa Pedrana; Joseph Doyle; Amanda Wade; Margaret Hellard
Journal:  J Virus Erad       Date:  2018-04-01

3.  The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.

Authors:  Adam Palayew; Samya R Stumo; Graham S Cooke; Sharon J Hutchinson; Marie Jauffret-Roustide; Mojca Maticic; Magdalena Harris; Ammal M Metwally; Homie Razavi; Jeffrey V Lazarus
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.240

4.  Hepatitis C services at harm reduction centres in the European Union: a 28-country survey.

Authors:  Juan M Pericàs; Daniel J Bromberg; Denise Ocampo; Eberhard Schatz; Iwona Wawer; Piotr Wysocki; Kelly Safreed-Harmon; Jeffrey V Lazarus
Journal:  Harm Reduct J       Date:  2019-03-21

5.  Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.

Authors:  Rachel Sacks-Davis; Joseph S Doyle; Andri Rauch; Charles Beguelin; Alisa E Pedrana; Gail V Matthews; Maria Prins; Marc van der Valk; Marina B Klein; Sahar Saeed; Karine Lacombe; Nikoloz Chkhartishvili; Frederick L Altice; Margaret E Hellard
Journal:  J Int AIDS Soc       Date:  2018-04       Impact factor: 5.396

6.  Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.

Authors:  Rob Bielen; Samya R Stumo; Rachel Halford; Klára Werling; Tatjana Reic; Heino Stöver; Geert Robaeys; Jeffrey V Lazarus
Journal:  Harm Reduct J       Date:  2018-05-11

7.  On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017.

Authors:  Christer Frode Aas; Jørn Henrik Vold; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Jan Magnus Økland; Rafael Alexander Modahl Leiva; Peter Vickerman; Kjell Arne Johansson; Lars T Fadnes
Journal:  BMJ Open       Date:  2020-08-26       Impact factor: 2.692
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.